The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Navigating U.S. healthcare insurance when treating patients with SCD
Jaap-Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses how he navigates the U.S. healthcare insurance system when treating patients with sickle cell disease (SCD). He particularly focuses on the complexities in relation to securing insurance approval for gene therapy treatments. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
